- Home
- INCY vs JEF Comparison
INCY vs JEF Comparison
Compare INCY & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- JEF
- Stock Information
- Founded
- INCY 1991
- JEF 1968
- Country
- INCY United States
- JEF United States
- Employees
- INCY N/A
- JEF N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- JEF Investment Bankers/Brokers/Service
- Sector
- INCY Health Care
- JEF Finance
- Exchange
- INCY Nasdaq
- JEF Nasdaq
- Market Cap
- INCY 17.0B
- JEF 10.5B
- IPO Year
- INCY 1993
- JEF N/A
- Fundamental
- Price
- INCY $105.57
- JEF $55.94
- Analyst Decision
- INCY Buy
- JEF Buy
- Analyst Count
- INCY 19
- JEF 4
- Target Price
- INCY $89.19
- JEF $71.00
- AVG Volume (30 Days)
- INCY 2.8M
- JEF 2.8M
- Earning Date
- INCY 10-28-2025
- JEF 09-29-2025
- Dividend Yield
- INCY N/A
- JEF 2.87%
- EPS Growth
- INCY 3878.02
- JEF 25.06
- EPS
- INCY 5.90
- JEF 2.92
- Revenue
- INCY $4,813,105,000.00
- JEF $7,231,501,000.00
- Revenue This Year
- INCY $19.33
- JEF $5.64
- Revenue Next Year
- INCY $10.47
- JEF $10.05
- P/E Ratio
- INCY $17.95
- JEF $19.13
- Revenue Growth
- INCY 18.09
- JEF 15.68
- 52 Week Low
- INCY $53.56
- JEF $39.28
- 52 Week High
- INCY $108.81
- JEF $82.68
- Technical
- Relative Strength Index (RSI)
- INCY 80.92
- JEF 50.04
- Support Level
- INCY $91.16
- JEF $52.09
- Resistance Level
- INCY $106.47
- JEF $54.82
- Average True Range (ATR)
- INCY 4.31
- JEF 1.70
- MACD
- INCY 1.48
- JEF 0.45
- Stochastic Oscillator
- INCY 88.14
- JEF 66.40
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.